Cell Culture

The World Market for Media, Sera, and Reagents

Publication Date	January 2007
Publisher	Kalorama Information
Product Type	Report
Pages	162
ISBN Number	not applicable
Product Code	KAL00034

Buy this product or for assistance call +44 20 7060 7474

PDF £2,345.00$3901 | €2625

PRINT £2,585.00$4300 | €2893

FAX Order above formats by FAX

Summary

This completely updated edition of this comprehensive and indispensable report covers the breadth of traditional IVD testing. The report contains complete market statistics and analysis for all areas of IVD, including:

Point-of-Care
Clinical Chemistry
Immunoassays
Molecular Assays
Hematology
Coagulation
Microbiology and Virology
Blood Banking
Histology and Cytology

Market size, growth, share, and geographic distribution, as well as trends in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Projections are made through 2010.

This new 1,000-page edition greatly expands coverage of the field and tracks the most important developments. Expanded or added in this edition are sections on:

the movement toward POC and decentralization in lab medicine
miniaturization and molecularization of devices
geo-economic and demographic influences on markets
non-invasive sampling
greatly expanded market data on PGx and SNP testing
revamped segmentation for clinical chemistry to include workstations and immunoanalyzers
more information about more immunoassays
the renewed interest in microbiology/virology based on resistance and the re-emergence of serious hospital- and community-based organisms
world blood banking developments
expanded sections on histology/cytology developments including emerging areas such as tissue microarrays, circulating tumor cells, and genomics-fueled innovation.

In addition, there are now profiles of more than established and emerging players in IVD with profiles of more than 421 companies, from the top tier to emerging and niche competitors to watch.

Content

Chapter One: Executive Summary
- The Importance of Biomarkers
- Speed Drug Development
- Predictive Diagnostics
- Key Applications
- Selected Clinical Trial Applications
- Key Diagnostics
- World Market Summary
- Clinical Diagnostics
- Clinical Trials
- Methodology
Chapter Two: Introduction
- In Perspective
- What Are Biomarkers?
- Surrogate Endpoints
- Types of Biomarkers
- Applications
- Diagnostics
- Drug Development
- Imaging Biomarkers
- Issues and Concerns
Chapter Three: Markets
- Overview
- Key Diagnostics Segments
- Cancer
- EGFR Testing
- Stroke
- Drug Development
- Clinical Trials
Chapter Four: Company Profiles
- Biophysical Corp.
- Charles River Laboratories Inc.
- Cyclacel Pharmaceuticals Inc.
- deCODE Genetics
- Enodar Biologic Corp.
- Health Discovery Corp.
- Illumina Inc.
- Imgenex Corp.
- Insilicos LLC
- Metabolon Inc.
- Millennium Pharmaceuticals Inc.
- Peakadilly
- PPD Inc.
- Proteome Sciences plc
- Rules-Based Medicine Inc.
- Targeted Molecular Diagnostics LLC
List of Exhibits
- Exhibit 1-1: World Market for Biomarkers in HER2 Breast Cancer Diagnostics 2006-2010
- Exhibit 1-2: World Market for Biomarkers in Ovarian Cancer Diagnostics 2006-2010
- Exhibit 1-3: World Market for Biomarkers in Cervical Cancer Diagnostics 2006-2010 Revenues (in millions)
- Exhibit 1-4: Summary: World Market for Biomarkers in Clinical Trials 2006-2010
- Exhibit 3-1: U.S. Market for HER2-Based Biomarkers for Breast Cancer 2006-2010
- Exhibit 3-2: World Market for HER2-Based Biomarkers for Breast Cancer 2006-2010 Revenues (in millions)
- Exhibit 3-3: US Market for Biomarkers for Ovarian Cancer 2006-2010
- Exhibit 3-4: Market for Biomarkers for Ovarian Cancer 2006-2010
- Exhibit 3-5: Market for Biomarkers for Cervical Cancer 2006-2010
- Exhibit 3-6: World Market for Biomarkers for Cervical Cancer 2006-2010
- Exhibit 3-7: US Market for Biomarkers for Prostate Cancer 2006-2010
- Exhibit 3-8: World Market for Biomarkers for Prostate Cancer 2006-2010
- Exhibit 3-9: US Market for Biomarkers for Bladder Cancer 2006-2010
- Exhibit 3-10: World Market for Biomarkers for Bladder Cancer 2006-2010
- Exhibit 3-11: US Market for Biomarkers for EGFR Testing 2006-2010
- Exhibit 3-12: World Market for Biomarkers for EGFR Testing 2006-2010
- Exhibit 3-13: US Market for Biomarkers for Stroke Diagnosis 2006-2010
- Exhibit 3-14: World Market for Biomarkers for Stroke Diagnosis 2006-2010
- Exhibit 3-15: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2006
- Exhibit 3-16 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2006
- Exhibit 3-17: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2007
- Exhibit 3-18 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2007
- Exhibit 3-19: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2008
- Exhibit 3-20 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2008
- Exhibit 3-21: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2009
- Exhibit 3-22 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2009
- Exhibit 3-23: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2010
- Exhibit 3-24 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2010